Trial Profile
Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 Powder for Oral Solution in Healthy Male Volunteers q.d. or b.i.d.for 14 Days (a Randomised, Double-blind, Placebo-controlled Within Dose Groups Phase I Trial)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Apr 2014
Price :
$35
*
At a glance
- Drugs BI 1015550 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 10 Apr 2014 New trial record